CLIENT NAME | DEAL TYPE | ACTION | DATE | AVG. PRICE | QUANTITY | EXCHANGE |
---|---|---|---|---|---|---|
ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Purchase | 2022-10-17 | 1378.65 | 80615 | BSE |
ISHARES MSCI INDIA SMALL-CAP ETF | Block | Purchase | 2022-10-17 | 1378.65 | 11841 | BSE |
ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 2022-10-17 | 1378.65 | 80615 | BSE |
Financials( ₹ in Cr) | Glaxosmithkline Pharmaceuticals Ltd | Sun Pharmaceuticals Industries Ltd | Cipla Ltd | Dr Reddys Laboratories Ltd | Zydus Lifesciences Ltd |
---|---|---|---|---|---|
Price | 1,946.60 | 1,620.55 | 1,496.95 | 6,157.90 | 1,007.35 |
% Change | 3.55 | 1.02 | 2.30 | 1.88 | 0.77 |
Mcap ₹ Cr | 32,976.57 | 388,824.23 | 120,856.26 | 102,719.31 | 101,964.37 |
Revenue TTM ₹ Cr | 3,251.72 | 43,885.68 | 15,790.60 | 24,669.70 | 17,237.40 |
Net Profit TTM ₹ Cr | 610.69 | 8,560.84 | 2,513.47 | 4,507.30 | 1,997.30 |
PE TTM | 51.32 | 41.45 | 30.52 | 19.64 | 30.51 |
1 Year Return | 53.46 | 64.78 | 68.33 | 37.28 | 109.04 |
ROCE | 33.92 | 16.79 | 14.76 | 25.99 | 16.25 |
ROE | 27.73 | 16.46 | 10.66 | 21.21 | 14.05 |
Equity Capital: 1,741.28 Cr FV: 10.00
Period | MF Net Purchase / (sold) | FII Net |
---|---|---|
LAST 1M | 29,068.81 | 33,709.58 |
LAST 3M | 68,518.10 | 30,558.15 |
LAST 6M | 130,081.93 | 64,349.19 |
LAST 12M | 189,941.35 | 208,211.24 |
Date | Action Type | Ratio |
---|---|---|
Jun 30, 2023 | Dividend | 320 |
Jul 07, 2022 | Dividend | 600 |
Jul 07, 2022 | Dividend | 300 |
GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.
GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.
In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.
GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030
Tel | : | 91-022-24959595 |
: | askus:gsk.com; ajay.a.nadkarni:gsk.com | |
Website | : | http://www.gsk-india.com |
Karvy Computershare Pvt Ltd
AGM Date (Month) | : | Jul |
Face Value Equity Shares | : | 10 |
Market Lot Equity Shares | : | 1 |
BSE Code | : | 500660 |
NSE Code | : | GLAXO |
Book Closure Date (Month) | : | |
BSE Group | : | A |
ISIN | : | INE159A01016 |
You can buy Glaxosmithkline Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glaxosmithkline Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:58 PM the closing price of Glaxosmithkline Pharmaceuticals Ltd was ₹ 1,946.60.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:58 PM, the market cap of Glaxosmithkline Pharmaceuticals Ltd stood at ₹ 32,976.57.
The latest PE ratio of Glaxosmithkline Pharmaceuticals Ltd as of Mar 28, 2024 03:58 PM is 51.32
The latest PB ratio of Glaxosmithkline Pharmaceuticals Ltd as of Mar 28, 2024 03:58 PM is 0.05
The 52-week high of Glaxosmithkline Pharmaceuticals Ltd share price is ₹ 2,524.00 while the 52-week low is ₹ 1,227.00